Lumacaftor Ivacaftor: Key Cystic Fibrosis Treatment Explained

Summary of Key Points

Lumacaftor/ivacaftor is a combination medication used to treat cystic fibrosis (CF) in patients with specific genetic mutations. This treatment works by improving the function of a defective protein in people with CF, which enhances lung function and reduces the frequency of lung infections. Always consult your healthcare provider before starting or adjusting your dose. Our telemedicine providers are available to assist with any questions regarding your treatment.

Names of Medication

US Brand Name: Orkambi

Generic Name: Lumacaftor/ivacaftor

The generic name refers to the chemical composition of the medication, while the brand name is assigned by the manufacturer. The generic name is often listed in parentheses.

Pharmacologic Category

CFTR Modulator (Cystic Fibrosis Transmembrane Conductance Regulator Modulator)

Other medications in the CFTR modulator category include:

1. Ivacaftor (Kalydeco)
2. Tezacaftor/Ivacaftor (Symdeko)
3. Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)

Dosing for Cystic Fibrosis Treatment

Cystic Fibrosis (CF)

Lumacaftor/ivacaftor is prescribed for the treatment of cystic fibrosis in patients aged 2 years and older who have two copies of the F508del mutation in the CFTR gene.

Adults and children 12 years and older: Take 2 tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) orally every 12 hours. Treatment is ongoing and should be continued as directed by your healthcare provider.

Children 6 to 11 years old: Take 2 tablets (each containing lumacaftor 100 mg/ivacaftor 125 mg) orally every 12 hours.

Children 2 to 5 years old: Take 1 packet of granules (each containing lumacaftor 100 mg/ivacaftor 125 mg) mixed with soft food or liquid every 12 hours.

Always follow your healthcare provider’s instructions regarding lumacaftor/ivacaftor dosage. Do not change your dose without consulting your doctor. If you need assistance, our telemedicine providers are available to help manage your treatment plan.

Dosage Forms and Strengths

Tablets: Lumacaftor 200 mg/Ivacaftor 125 mg

Tablets: Lumacaftor 100 mg/Ivacaftor 125 mg

Oral granules: Lumacaftor 100 mg/Ivacaftor 125 mg per packet

Administration Instructions

Lumacaftor/ivacaftor should be taken with fat-containing food to improve absorption. Examples of fat-containing foods include eggs, avocados, nuts, and butter. Swallow the tablets whole; do not crush or chew them. If using the granules, mix them with soft food or liquid and consume immediately. If you miss a dose, take it as soon as you remember. However, if it’s almost time for your next dose, skip the missed dose. Do not take two doses at once.

Contraindications

A contraindication is a specific situation or condition where a medication should not be used because it may cause harm. It’s important to be aware of contraindications to ensure the medication is safe for you.

Here are the contraindications for taking Lumacaftor/ivacaftor:

1. Severe liver impairment: Patients with severe liver problems (such as cirrhosis) should not take Lumacaftor/ivacaftor because the medication is processed by the liver. If the liver is not functioning properly, the drug can accumulate to dangerous levels in the body, leading to serious side effects.
2. Hypersensitivity to Lumacaftor, Ivacaftor, or any of the ingredients: If you have had an allergic reaction to Lumacaftor/ivacaftor or any of its components, you should not take this medication. Allergic reactions can range from mild skin rashes to severe, life-threatening conditions like anaphylaxis.
3. Use of strong CYP3A inducers: Medications that strongly induce the enzyme CYP3A (such as rifampin or St. John’s Wort) can reduce the effectiveness of Lumacaftor/ivacaftor. This is because CYP3A inducers speed up the breakdown of the medication, making it less effective.

Drug-to-Drug Interactions

Some medications can interact with Lumacaftor/ivacaftor, either reducing its effectiveness or increasing the risk of side effects. Here are some common drug interactions:

1. Rifampin (Rifadin): This antibiotic is a strong CYP3A inducer and can reduce the effectiveness of Lumacaftor/ivacaftor.
2. St. John’s Wort: A herbal supplement that also induces CYP3A and can lower the effectiveness of Lumacaftor/ivacaftor.
3. Warfarin (Coumadin): Lumacaftor/ivacaftor can affect how your body processes warfarin, a blood thinner, potentially increasing the risk of bleeding or clotting issues.
4. Oral contraceptives (birth control pills): Lumacaftor/ivacaftor can reduce the effectiveness of hormonal birth control, increasing the risk of unintended pregnancy. It’s recommended to use a non-hormonal method of contraception while taking this medication.
5. Azole antifungals (e.g., ketoconazole): These medications can increase the levels of ivacaftor in the blood, potentially leading to more side effects.

Lumacaftor/Ivacaftor in Pregnancy

Is it safe to take Lumacaftor/Ivacaftor during pregnancy?

The safety of Lumacaftor/Ivacaftor during pregnancy has not been fully established. While animal studies suggest there may be some risks, data on its effects in pregnant humans remain limited. If you are pregnant or planning to become pregnant, it’s important to discuss the potential risks and benefits with your healthcare provider. They can help you carefully weigh the advantages of continuing this cystic fibrosis treatment against any possible risks to your baby. If you need to consult a provider, we offer telemedicine consultations to support you in making an informed decision.

Lumacaftor/Ivacaftor While Breastfeeding

Is it safe to take Lumacaftor/Ivacaftor while breastfeeding?

It is currently unknown whether Lumacaftor/Ivacaftor passes into breast milk. Due to the potential for serious side effects in a nursing infant, it is generally recommended to either discontinue breastfeeding or stop taking the medication. This decision should be made in close consultation with your healthcare provider, who can help you assess the risks and benefits specific to your situation. If you have any concerns, our telemedicine team is available to provide guidance and support.

Estimated Cost of Lumacaftor/Ivacaftor Medication

The cost of Lumacaftor/Ivacaftor (Orkambi) can be substantial without insurance coverage. With a GoodRx coupon, the estimated cost for a 30-day supply of Orkambi medication ranges from $20,000 to $25,000. Prices may vary depending on the pharmacy and your location. Be sure to check with your insurance provider or local pharmacy for more accurate pricing information.

Possible Alternatives to Lumacaftor/Ivacaftor

For individuals with cystic fibrosis, Lumacaftor/Ivacaftor may not be the only treatment option. Here are some potential alternatives or lifestyle changes that may help manage the condition:

1. Other CFTR Modulators: Medications such as ivacaftor (Kalydeco) or tezacaftor/ivacaftor (Symdeko) may be considered as alternatives, depending on the specific genetic mutation causing cystic fibrosis. Your healthcare provider can help determine the most appropriate medication for your needs.
2. Airway Clearance Techniques: These include chest physiotherapy, postural drainage, and devices like the Flutter or Acapella, which help clear mucus from the lungs.
3. Inhaled Medications: Inhaled bronchodilators, mucolytics, and antibiotics can help manage lung infections and improve breathing.
4. Exercise: Regular physical activity can enhance lung function and overall health in individuals with cystic fibrosis.
5. Nutritional Support: A high-calorie, high-protein diet, along with pancreatic enzyme supplements, can help manage the digestive challenges associated with cystic fibrosis.

Before making any changes to your treatment plan, it’s essential to discuss these options with your healthcare provider. If you need assistance, our telemedicine team is available to help you explore these alternatives and make informed decisions about your care.

Recent Updates on Lumacaftor/Ivacaftor Research

Recent research on Lumacaftor/Ivacaftor has focused on its long-term effects and its use in younger populations. Studies indicate that starting Lumacaftor/Ivacaftor in children as young as 2 years old can improve lung function and reduce the frequency of pulmonary exacerbations. Additionally, ongoing research is exploring the potential benefits of combining Lumacaftor/Ivacaftor with other CFTR modulators to further enhance outcomes for cystic fibrosis patients.

As new studies are published, staying informed about the latest developments is crucial. If you have questions about how recent research might impact your treatment plan, our telemedicine providers are here to help you understand the latest findings and make well-informed decisions about your care.

James Kingsley

Learn More